Key Points
- Director Herm Rosenman sold 48,419 Natera shares on Dec. 12 at an average $227.42 for roughly $11.01M, cutting his ownership by 70.42% to 20,342 shares (worth about $4.63M).
- Natera reported quarterly EPS of ($0.64) versus ($0.39) expected but beat on revenue with $592.18M (up 34.7% YoY), while showing a negative net margin (−14.61%) and negative ROE (−25.07%).
- Analyst sentiment is generally positive — MarketBeat shows a "Moderate Buy" consensus with an average target of $229.12, and multiple firms have recently raised price targets (e.g., UBS $280, Morgan Stanley $265).
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 4,692 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92. Following the completion of the transaction, the insider directly owned 113,065 shares of the company's stock, valued at $26,090,879.40. This trade represents a 3.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total transaction of $714,450.00.
- On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.
- On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
- On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.
- On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The stock was sold at an average price of $187.95, for a total transaction of $54,881.40.
- On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $159.99, for a total value of $479,970.00.
Natera Stock Down 0.4%
NASDAQ NTRA opened at $227.40 on Wednesday. The company has a market cap of $31.45 billion, a price-to-earnings ratio of -99.30 and a beta of 1.63. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $246.90. The business's fifty day moving average is $209.04 and its 200 day moving average is $177.74.
Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera's revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on NTRA. JPMorgan Chase & Co. raised their price objective on shares of Natera from $250.00 to $260.00 and gave the company an "overweight" rating in a report on Monday. Stephens raised their price target on shares of Natera from $197.00 to $235.00 and gave the company an "overweight" rating in a research note on Thursday, November 13th. Zacks Research lowered shares of Natera from a "hold" rating to a "strong sell" rating in a report on Monday, October 20th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, Evercore ISI raised their target price on Natera from $190.00 to $250.00 and gave the stock an "outperform" rating in a research report on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $229.12.
View Our Latest Analysis on NTRA
Institutional Investors Weigh In On Natera
Several large investors have recently modified their holdings of NTRA. Park Avenue Securities LLC acquired a new position in Natera during the second quarter worth $1,525,000. Baird Financial Group Inc. increased its position in shares of Natera by 277.8% during the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company's stock worth $4,498,000 after acquiring an additional 19,576 shares in the last quarter. Atria Investments Inc raised its holdings in shares of Natera by 30.1% in the 2nd quarter. Atria Investments Inc now owns 13,242 shares of the medical research company's stock worth $2,237,000 after acquiring an additional 3,063 shares during the last quarter. Zweig DiMenna Associates LLC lifted its position in Natera by 3.0% in the 2nd quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company's stock valued at $20,965,000 after acquiring an additional 3,610 shares in the last quarter. Finally, Comerica Bank boosted its stake in Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock valued at $19,954,000 after purchasing an additional 27,379 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
